HGH Fragment
AOD-9604:
HGH Fragment for Targeted Fat Loss
The C-terminal fragment of human growth hormone — isolated for its lipolytic activity alone. AOD-9604 delivers HGH's fat-burning mechanism without affecting blood sugar, IGF-1, or insulin sensitivity. The precision fat loss peptide.
01
What AOD-9604 Actually Does
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177–191 of the C-terminus of human growth hormone (hGH). It was developed by Metabolic Pharmaceuticals in Australia, initially progressing through Phase IIb clinical trials for obesity treatment. While it did not receive regulatory approval for obesity (largely due to economic rather than safety reasons), it established an extensive safety and efficacy record that makes it one of the most well-characterized fat loss peptides in research use.
The conceptual elegance of AOD-9604 is in its fragment strategy. Full HGH is a 191-amino-acid protein with multiple domains that produce different effects: the N-terminal region drives IGF-1 production, protein synthesis, and the insulin-like metabolic effects. The C-terminal region (amino acids 177–191) contains the lipolytic activity — the ability to stimulate fat breakdown. AOD-9604 is essentially this lipolytic domain extracted and synthesized independently.
The result is a compound that delivers HGH's fat loss mechanism with remarkable selectivity: no blood glucose effects, no IGF-1 elevation, no anabolic effects on muscle, and none of the insulin resistance that high-dose synthetic HGH can induce. Clinical trials confirmed this profile — AOD-9604 reduced body fat in human subjects without meaningful changes in blood glucose, IGF-1, or other hormonal markers associated with full HGH use.
For looksmaxxers and body recomposition seekers, this means targeted fat reduction — particularly from the face, midsection, and troublesome fat deposits — without the hormonal complexity of full HGH protocols, and without the appetite suppression (and associated discomfort) of GLP-1 agonists like semaglutide or tirzepatide.
Beta-3 Adrenergic Receptor Activation
AOD-9604 activates beta-3 adrenergic receptors (β3-AR) expressed on adipocytes — fat cells. β3-AR activation triggers a cAMP-mediated signaling cascade that activates hormone-sensitive lipase (HSL), the primary enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol. These mobilized fatty acids are then available for oxidation as energy. β3-AR agonism is the same mechanism exploited by thermogenic compounds, but AOD-9604 achieves it through a peptide that mimics GH's fat-mobilizing domain without systemic adrenergic stimulation.
Lipogenesis Inhibition
Beyond stimulating fat breakdown, AOD-9604 simultaneously inhibits lipogenesis — the conversion of dietary carbohydrates and other substrates into stored fat. This dual mechanism (increased lipolysis + decreased lipogenesis) creates a powerful fat-reducing environment that operates independently of caloric intake. While caloric control amplifies results, AOD-9604 produces fat loss benefits even in eucaloric (maintenance) settings — a property not shared by most fat loss interventions.
No IGF-1 or Insulin-Like Effects
Full HGH's fat-releasing and anabolic effects reside in different parts of the molecule. The N-terminal region drives IGF-1 upregulation and insulin-like metabolic effects (which can cause insulin resistance with supraphysiological dosing). The C-terminal region (which AOD-9604 replicates) contains only the lipolytic activity. AOD-9604 therefore delivers HGH's fat loss mechanism in isolation — without affecting blood glucose regulation, insulin sensitivity, or IGF-1 levels.
Cartilage Repair Properties
Research has identified that AOD-9604 promotes cartilage repair and may have chondroprotective properties independent of its fat loss mechanisms. Studies suggest AOD-9604 stimulates proteoglycan synthesis in cartilage tissue, potentially making it useful as an adjunct for joint health alongside its primary body composition applications. This positions AOD-9604 as a uniquely dual-purpose compound: fat loss primary with joint support secondary.
02
AOD-9604 vs. Full HGH vs. Semaglutide
AOD-9604, full HGH, and GLP-1 agonists (semaglutide, tirzepatide) all produce fat loss through entirely different mechanisms. Understanding the differences clarifies AOD-9604's unique niche: targeted lipolysis without hormonal complexity or appetite manipulation.
| Metric | AOD-9604 | Full HGH | Semaglutide |
|---|---|---|---|
| Primary mechanism | β3-AR activation / lipolysis | IGF-1, protein synthesis, lipolysis | GLP-1 receptor agonist / appetite |
| IGF-1 elevation | None | High | None |
| Blood sugar effect | None | Increases (high doses) | Decreases |
| Muscle preservation | Indirect (via GH receptor) | Strong (anabolic) | Partial (GLP-1 effects) |
| Appetite effect | None | None | Strong suppression |
| Fat loss speed | Gradual, sustainable | Moderate | Rapid |
| Joint health | Positive (chondroprotective) | Positive | None |
| Best use case | Targeted fat loss, recomp | Full body optimization | Rapid weight loss, metabolic |
When to Choose AOD-9604
AOD-9604 is the optimal choice when the goal is targeted fat reduction without hormonal complexity, appetite suppression, or the risks of supraphysiological GH. It excels for individuals who are metabolically healthy but seeking body recomposition improvement — particularly those focused on facial aesthetics and body fat reduction while preserving muscle. It is not ideal for those seeking rapid weight loss (semaglutide performs this role better) or comprehensive anabolic optimization (full GH or IGF-1 protocols serve that role).
03
Dosing Protocols
Fat Loss Protocol (Primary)
DOSE
250–500mcg SubQ
TIMING
Morning fasted, immediately upon waking
DURATION
12–16 weeks
The fasted morning injection leverages the overnight fasted state to maximize lipolysis. Follow with 30–45 minutes of fasted cardio or delay first meal by 30+ minutes for amplified effect. Caloric deficit of 300–500 calories enhances results significantly.
Body Recomposition Protocol
DOSE
250mcg AM fasted + 250mcg pre-sleep
TIMING
Split dosing — morning and evening
DURATION
12–20 weeks
Twice daily dosing provides more consistent lipolytic signaling throughout the day. Evening dose leverages overnight fasted catabolism of mobilized fat. Combine with CJC-1295/Ipamorelin in the evening dose for muscle preservation.
Looksmaxxing Recomp Stack
DOSE
AOD-9604 300mcg AM + CJC-1295/Ipamorelin 200mcg PM
TIMING
AM fasted / PM pre-sleep
DURATION
12–16 weeks
The definitive body recomposition stack for looksmaxxing. AOD-9604 drives facial and body fat reduction; CJC-1295/Ipamorelin improves muscle quality, skin tightening, and recovery. Together they create simultaneous fat loss and muscle quality improvement.
04
Results Timeline
Weeks 1–2
FAT LOSS / BODY COMPOSITION
Cellular lipolysis activation beginning. No visible fat loss yet — fatty acid mobilization has increased but visible changes require weeks of consistent use.
OTHER EFFECTS
Some users report slightly increased morning energy from enhanced fat oxidation. No appetite effects. No hormonal changes.
Weeks 3–6
FAT LOSS / BODY COMPOSITION
Early fat loss noticeable on scale and by feel. Midsection feeling slightly less full. Facial definition may be slightly improved in individuals starting at higher body fat.
OTHER EFFECTS
Recovery feeling slightly improved. If stacked with CJC/Ipamorelin, sleep improvements becoming evident. Energy during fasted cardio improved.
Weeks 7–12
FAT LOSS / BODY COMPOSITION
Clear visible fat loss. Abdominal definition improving. Facial jawline and cheekbone definition more visible. Body fat percentage measurably reduced.
OTHER EFFECTS
Peak lipolytic effect. Skin quality improving, particularly if stacked with GH secretagogues. Joint comfort maintained or improved due to chondroprotective effects.
Weeks 13–20
FAT LOSS / BODY COMPOSITION
Continued gradual fat reduction. Maximum body recomposition benefit with extended protocol. Some users report plateau — implement diet adjustments or compound rotation.
OTHER EFFECTS
Cumulative body composition transformation. When combined with muscle-building compounds, recomposition (simultaneous fat loss + muscle gain) becomes clearly visible.
05
Who Is AOD-9604 For?
AOD-9604 occupies a specific niche in the fat loss peptide landscape. It is most valuable for individuals who are already at a reasonable body composition and seeking the final level of refinement — facial definition, abdominal detail, and overall leanness — that is difficult to achieve through diet and training alone. It is less suited to individuals seeking dramatic rapid weight loss, for whom GLP-1 agonists (semaglutide, tirzepatide, retatrutide) are more appropriate.
Ideal Candidates
- ✓Individuals at moderate body fat seeking further reduction (15–25% BF)
- ✓Looksmaxxers focused on facial and body definition
- ✓Athletes in body composition optimization phases
- ✓Individuals who cannot tolerate appetite-suppressing compounds
- ✓Diabetics or pre-diabetics concerned about blood sugar effects of HGH
- ✓Body recompositioners wanting fat loss alongside muscle development
Less Optimal Candidates
- ✗Individuals with significant obesity seeking primary weight loss
- ✗Those expecting rapid dramatic fat loss
- ✗Individuals under 20 with naturally high GH levels
- ✗Those expecting appetite suppression as a benefit
- ✗Individuals with active cancer or GH-sensitive conditions
- ✗Those unwilling to commit to 12+ week protocols
06
AOD-9604 for Looksmaxxing
Facial aesthetics are disproportionately determined by fat distribution. Facial fat — particularly submental, buccal, and infraorbital — directly affects the perception of jaw definition, cheekbone prominence, and overall facial attractiveness. These fat deposits are among the most lipolytically responsive to AOD-9604's β3-AR mechanism, making AOD-9604 one of the most targeted non-surgical facial refinement tools available.
Facial Fat Reduction
Facial fat — particularly submental (under chin), jowl, and buccal fat — contributes significantly to the perception of aging and reduced facial definition. AOD-9604's lipolytic effect applies to all adipose tissue, including facial fat deposits. Over 12–20 weeks, meaningful reduction in facial adiposity produces sharper jawline definition, higher cheekbone visibility, and reduced midface heaviness — all core looksmaxxing outcomes.
Abdominal Definition
Visceral and subcutaneous abdominal fat is among the most lipolytically responsive fat depots to β3-AR activation. AOD-9604 produces preferential mobilization of abdominal fat, contributing to the lean midsection aesthetics central to looksmaxxing physique goals. This effect is amplified by fasted cardio in the post-injection window.
No Muscle Loss During Cut
One of looksmaxxing's critical challenges is losing fat without the muscle loss that reduces aesthetic impact. AOD-9604's mechanism targets fat tissue directly without affecting muscle protein synthesis or nitrogen balance. When stacked with GH secretagogues (CJC-1295/Ipamorelin), the muscle-preserving GH signal actively counteracts the muscle-wasting risk of caloric restriction.
Skin Tightening via GH Pathway
AOD-9604 retains some GH receptor binding activity that does not translate to IGF-1 elevation but may contribute to collagen synthesis signaling. Users report that fat loss from AOD-9604 tends to be accompanied by skin tightening rather than the loose skin that can follow rapid fat loss — a critically important distinction for looksmaxxing where skin quality is as important as fat reduction.
Looksmaxxing Recomposition Protocol
07
Stacking AOD-9604 with CJC-1295/Ipamorelin
AOD-9604 and CJC-1295/Ipamorelin work through completely independent mechanisms and are the definitive body recomposition stack. AOD-9604 drives fat mobilization and lipolysis. CJC-1295/Ipamorelin drives GH pulse optimization, muscle preservation, skin quality, and recovery. Combined, they create a simultaneous fat loss and muscle quality environment — body recomposition — that is difficult to achieve through any single compound or traditional dietary approaches.
AOD-9604
Targeted lipolysis
DOSE
250–500mcg AM fasted
TIMING
Morning
BENEFIT
Fat mobilization, lipogenesis inhibition
CJC-1295
GHRH receptor activation
DOSE
200mcg pre-sleep
TIMING
Evening
BENEFIT
GH pulse amplification, recovery
Ipamorelin
GHS-R1a agonist
DOSE
200mcg pre-sleep
TIMING
Evening (with CJC)
BENEFIT
Clean GH pulse, skin quality, sleep
Why This Stack Works So Well
Body recomposition — the simultaneous loss of fat and gain (or preservation) of muscle — is normally constrained by the fact that caloric deficit for fat loss conflicts with the anabolic surplus required for muscle growth. This stack partially circumvents this constraint: AOD-9604 mobilizes stored fat as an energy source (reducing the actual caloric deficit your body experiences), while CJC-1295/Ipamorelin maintains the anabolic hormonal environment for muscle quality. The result is a fat loss rate faster than expected from caloric intake, while muscle is preserved or improved.
08
Safety Profile & Side Effects
AOD-9604 has one of the cleanest safety profiles in the peptide research space, validated across multiple human clinical trials. The compound was administered to human subjects across Phase IIa and IIb trials at doses ranging from 1mg/kg orally without significant adverse events. At the substantially lower subcutaneous doses used in research protocols (250–500mcg), side effects are minimal.
Injection Site Reactions
Mild, commonMild redness, itching, or bruising at the subcutaneous injection site. Rotate sites daily. Use appropriate gauge needle (29–31G).
Headache
OccasionalMild headache reported by some users, particularly early in the protocol. Typically resolves within the first week. Usually related to the metabolic shift associated with increased fat oxidation.
Fatigue (Initial)
Occasional, earlyBrief period of mild fatigue in the first 1–2 weeks as the body adapts to increased fat mobilization for fuel. Resolves quickly and typically reverses to increased energy.
No Hormonal Effects
Not applicableAOD-9604 does not affect IGF-1, insulin, testosterone, estrogen, cortisol, prolactin, or thyroid hormones. No hormone management compounds are required.
FDA GRAS Status
AOD-9604 received Generally Recognized As Safe (GRAS) status from the FDA — a designation reflecting the extensive safety data accumulated through clinical trials. This is an unusual and meaningful designation for a research peptide, confirming the safety validation achieved during the drug development process even though the compound never proceeded to final drug approval.
Get AOD-9604
AOD-9604
Pharmaceutical-grade lyophilized AOD-9604. Certificate of analysis verified. The precision fat loss peptide for body recomposition and looksmaxxing.
Buy AOD-9604 →CJC-1295 + Ipamorelin
Stack with AOD-9604 for the definitive body recomposition protocol. Fat loss + GH optimization + muscle preservation.
10
Frequently Asked Questions
Can AOD-9604 be taken orally?
AOD-9604 was originally developed as an oral compound and the clinical trials demonstrating fat loss used oral administration. However, oral peptide bioavailability is significantly lower than subcutaneous injection due to gastrointestinal peptide degradation. Most research protocols use subcutaneous injection for more consistent and reliable results at lower doses. Some users take higher oral doses, but subcutaneous administration at 250–500mcg is the established research standard.
Does AOD-9604 require dietary changes to work?
AOD-9604 produces fat loss effects independently of diet — it is genuinely lipolytic. However, results are substantially amplified by a modest caloric deficit (300–500 calories below maintenance). At maintenance calories, AOD-9604 produces body recomposition: fat loss with weight stability, as mobilized fat is replaced by maintained or gained lean mass. In caloric surplus, fat loss may be partially offset by dietary fat storage, though the lipolysis still occurs.
Is AOD-9604 safe for diabetics?
AOD-9604's most important property for diabetics is its lack of blood glucose effect. Unlike full HGH, which can induce insulin resistance and raise blood glucose at supraphysiological doses, AOD-9604 does not affect insulin signaling or blood glucose regulation. Clinical trials specifically evaluated diabetic safety endpoints and found no adverse metabolic effects. However, any peptide protocol in diabetics should be discussed with a managing physician.
Will AOD-9604 cause muscle loss?
AOD-9604 does not cause muscle loss — it is not catabolic. Its lipolytic mechanism specifically targets adipose tissue. There is no mechanism by which AOD-9604 increases muscle protein breakdown. When used alone in a caloric deficit, muscle preservation depends on training and protein intake as usual. When stacked with CJC-1295/Ipamorelin, the GH-mediated anabolic environment actively supports muscle preservation during fat loss.
How should I time AOD-9604 around training?
The most effective protocol for training individuals is: inject AOD-9604 fasted in the morning, then train in a fasted state for 30–45 minutes (typically low-intensity cardio) to oxidize the mobilized fatty acids. This combination leverages the mobilized fat directly as training fuel, maximizing fat oxidation efficiency. If training later in the day, inject AOD-9604 2+ hours after the previous meal in a fasted state for the same effect.
Related Guides
Retatrutide Recomposition Guide →
The GLP-1/GIP/GCG triple agonist — compare rapid weight loss vs AOD-9604 precision fat loss
CJC-1295 + Ipamorelin Guide →
The muscle quality and recovery stack that completes the AOD-9604 recomposition protocol
Semaglutide Complete Guide →
Compare GLP-1-mediated weight loss with AOD-9604's targeted lipolytic approach
Daily Looksmaxxing Protocol →
Where AOD-9604 fits in the complete daily peptide and optimization schedule
All Peptide Guides →
Browse every in-depth protocol and research article on PeptidesMuscle
